Medicare will start covering Senseonics’ implantable continuous glucose monitor (CGM) for a broader group of patients from late February.
Last year, Medicare updated its policy to cover CGMs for people who take basal insulin or who have a history of hypoglycemia. Now, three Medicare Administrative Contractors (MACs) — Noridian, Palmetto and National Government Services —now cover the devices for people who only take basal insulin, or who don’t take insulin but have a history of hypoglycemia.
Currently, Senseonics is the only company with a Food and Drug Administration-approved implantable CGM. Their Eversense E3 CGM is implanted under the skin, and lasts for up to six months. The company claims that users don’t need to regularly insert a CGM and reorder supplies.
To find out more, CLICK HERE.
